Acyclovir-resistant chronic mucocutaneous herpes with good response to the association with imiquimod in an AIDS patient: case report

Oliveira, Suellen Ramos de; Assoni, Ariane Sponchiado; Vargas, Thiago Jeunon de Sousa; Daxbacher, Egon Luiz Rodrigues

doi:10.1016/j.abd.2020.10.019

Cited by 2 publications

(2 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Additionally, imiquimod is a potent agonist for TLR-7 that triggers strong immune responses via recognition of the HSV in the infected cells [ 57 ]. Topical imiquimod 5% was successfully used in some HIV patients with acyclovir-resistant anogenital HSV infection [ 116 ]. Furthermore, vegetative chronic genital herpes in HIV patients may be responsive to Imiquimod 5% [ 117 ].…”

Section: Treatment Guidelines and Resistant Pathogensmentioning

confidence: 99%

Fascinating Molecular and Immune Escape Mechanisms in the Treatment of STIs (Syphilis, Gonorrhea, Chlamydia, and Herpes Simplex)

Scurtu

Jinga

Simionescu

2022

IJMS

View full text Add to dashboard Cite

The incidence of syphilis, gonorrhea, chlamydia, and herpes simplex has increased over the last decade, despite the numerous prevention strategies. Worldwide scientists report a surge in drug-resistant infections, particularly in immunocompromised patients. Antigenic variations in syphilis enable long-term infection, but benzathine penicillin G maintains its efficiency, whereas macrolides should be recommended with caution. Mupirocin and zoliflodacin were recently introduced as therapies against ceftriaxone-resistant gonococcus, which poses a larger global threat. The gastrointestinal and prostatic potential reservoirs of Chlamydia trachomatis may represent the key towards complete eradication. Similar to syphilis, macrolides resistance has to be considered in genital chlamydiosis. Acyclovir-resistant HSV may respond to the novel helicase-primase inhibitors and topical imiquimod, particularly in HIV-positive patients. Novel drugs can overcome these challenges while nanocarriers enhance their potency, particularly in mucosal areas. This review summarizes the most recent and valuable discoveries regarding the immunopathogenic mechanisms of these sexually transmitted infections and discusses the challenges and opportunities of the novel molecules and nanomaterials.

show abstract

Section: Treatment Guidelines and Resistant Pathogensmentioning

confidence: 99%

Fascinating Molecular and Immune Escape Mechanisms in the Treatment of STIs (Syphilis, Gonorrhea, Chlamydia, and Herpes Simplex)

Scurtu

Jinga

Simionescu

2022

IJMS

View full text Add to dashboard Cite

show abstract

“…Intralesional cidofovir (diluted with saline to 15 mg/ml and injected until blanching seen) may also be useful. Topical 5% imiquimod cream has also shown some utility, possibly by increasing local immunity via augmented interferon alpha [11 ▪ ].…”

Section: Therapeuticsmentioning

confidence: 99%

Resistant herpes simplex virus infections – who, when, and what's new?

Kotton

2022

Current Opinion in Infectious Diseases

View full text Add to dashboard Cite

Purpose of reviewThis review summarizes the literature on acyclovir resistant herpes infections and the most recent data pertinent to diagnosis and treatment in the immunocompromised patient population. Recent findingsAlthough fairly rare, acyclovir resistant herpes infections can be challenging to diagnose. Clinicians should be aware of this entity when facing refractory herpes infections. With updated diagnostics, the diagnosis is usually made through viral culture and sequencing. Therapeutic choices depend on the extent of disease. Topical therapy may be appropriate for mucocutaneous disease. Intravenous antiviral therapies such as foscarnet and cidofovir may be necessary for disseminated, ophthalmologic, central nervous system, or visceral disease. Experimental therapies such as pritelivir are in clinical trials.

show abstract

Acyclovir-resistant chronic mucocutaneous herpes with good response to the association with imiquimod in an AIDS patient: case report

Cited by 2 publications

References 9 publications

Fascinating Molecular and Immune Escape Mechanisms in the Treatment of STIs (Syphilis, Gonorrhea, Chlamydia, and Herpes Simplex)

Fascinating Molecular and Immune Escape Mechanisms in the Treatment of STIs (Syphilis, Gonorrhea, Chlamydia, and Herpes Simplex)

Resistant herpes simplex virus infections – who, when, and what's new?

Contact Info

Product

Resources

About